REMODEL — Semaglutide mechanism-of-action MRI and biopsy trial in type 2 diabetes with CKD (2026) — Trial Summary

REMODEL — Semaglutide mechanism-of-action MRI and biopsy trial in type 2 diabetes with CKD (2026): Randomized, placebo-controlled, 2:1 mechanistic trial of subcutaneous semaglutide 1.0 mg once weekly versus placebo for 52 weeks in adults with type 2 diabetes and chronic kidney disease (eligibility a

References

NephroResource

Taking longer than expected

If you're on a slow connection or this keeps happening, tap below to reload.